Blood Based Biomarkers Market is expected to Hit US$ 41.43 Billion by 2035 | Major Companies - Guardant Health, Inc., Abbott, F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc

DataM Intelligence has unveiled its latest report on the "Blood Based Biomarkers Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Unlock Strategic Partnerships in the Growing Blood Based Biomarkers Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/blood-based-biomarkers-market?sz

The Global Blood Based Biomarkers Market size reached US$ 10.78 billion in 2025 and is expected to reach US$ 41.43 billion by 2035, growing with a CAGR 14.2% during the forecast period 2026-2035.

The Blood Based Biomarkers Market refers to the industry focused on the development, production, and commercialization of biomarkers detectable in blood samples for disease diagnosis, prognosis, treatment monitoring, and risk assessment. These biomarkers support early detection of conditions such as cancer, cardiovascular disorders, neurological diseases, and infectious diseases. Market growth is driven by advances in precision medicine, liquid biopsy technologies, rising chronic disease prevalence, and increasing demand for minimally invasive diagnostic solutions.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/blood-based-biomarkers-market?sz

Recent Industry Developments: United States

✅ May 2026: Lucent Diagnostics collaborated with Tempus AI to incorporate Alzheimer's blood biomarker testing into AI-enabled clinical platforms, improving early disease detection and biomarker-guided care pathways.

✅ April 2026: GRAIL partnered with Epic Systems to integrate the Galleri multi-cancer blood test into electronic health record systems, expanding physician access and supporting broader adoption of blood-based cancer biomarkers in clinical workflows.

✅ April 2026: Superpower announced a strategic partnership with GRAIL to provide wider access to blood-based multi-cancer early detection screening, accelerating preventive diagnostics adoption in the U.S. market.

Recent Industry Developments: Japan

✅ April 2026: Sysmex Corporation launched the HISCL p-Tau217 assay kit for blood-based Alzheimer's biomarker detection, strengthening development of minimally invasive neurological diagnostics and expanding future rollout into Japan and global markets.

✅ April 2026: The Bio-Hermes-002 study added Siemens Healthineers as a partner to advance evaluation of blood-based biomarkers for Alzheimer's disease, strengthening biomarker research collaboration relevant to the Japanese precision diagnostics ecosystem.

✅ March 2026: Epigenica AB signed a distribution agreement with PrimeTech Co., Ltd. to expand biomarker discovery technologies across Japan, supporting epigenetic research and precision medicine applications.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/blood-based-biomarkers-market?sz

List of the Key Players in the Blood Based Biomarkers Market:

Guardant Health, Inc.
GRAIL, Inc.
Natera, Inc.
Foundation Medicine, Inc.
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
QIAGEN
Abbott
Siemens Healthcare Private Limited
bioMérieux
Beckman Coulter, Inc
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Sysmex Europe SE.
Freenome Holdings, Inc.
Labcorp
Quest Diagnostics Incorporated.
Exact Sciences Corporation.
Tempus
Personalis, Inc.

How Does Market Research Work in the Blood Based Biomarkers Market?

Market research for the Blood Based Biomarkers Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of Blood Based Biomarkers Market:

✅ March 2026: Agilent Technologies to Acquire Biocare Medical (US$ 950 Million)
➠ Agilent announced the acquisition of Biocare Medical to strengthen its pathology and diagnostics portfolio. Biocare develops tissue diagnostic products, antibodies, and staining systems used in cancer detection and biomarker analysis. The deal expands Agilent's biomarker testing and precision diagnostics capabilities, supporting oncology biomarker development and disease identification.

✅ February 2026: Danaher to Acquire Masimo (US$ 9.9 Billion)
➠ Danaher agreed to acquire Masimo in one of the largest diagnostics deals of 2026. Masimo's non-invasive monitoring technologies, including blood-oxygen measurement platforms, add to Danaher's diagnostics portfolio. The acquisition reflects growing investment in biomarker-driven monitoring and advanced diagnostic technologies.

✅ January 2026: AstraZeneca Acquires Modella AI (Financial Terms Undisclosed)
➠ AstraZeneca acquired AI company Modella AI to accelerate oncology drug development and biomarker discovery. Modella's AI models support patient stratification, pathology analysis, and identification of targeted biomarkers, strengthening AstraZeneca's precision medicine and blood-based biomarker research capabilities.

Segments Covered in the Blood Based Biomarkers Market 2026:

By Biomarker Type: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Epigenetic Biomarkers, Cell Free DNA, Circulating Tumor DNA, Circulating Tumor Cells, Multi Biomarker Panels, Others.

By Disease Area: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Autoimmune Diseases, Metabolic Disorders, Prenatal Health, Others.

By Application: Screening, Diagnosis, Risk Stratification, Prognosis, Therapy Selection, Companion Diagnostics, Treatment Monitoring, Recurrence Monitoring.

By Technology: PCR, NGS, ELISA, Immunoassays, Mass Spectrometry, Proteomics Platforms, Others.

By Sample Type: Plasma, Serum, Whole Blood.

By End User: Hospitals, Diagnostic Laboratories, Cancer Centers, Pharma and Biotechnology Companies, CROs, Research Institute.

Regional Analysis of the Blood Based Biomarkers Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=blood-based-biomarkers-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Blood Based Biomarkers Market in 2025?
◆ What is the projected growth rate of the Blood Based Biomarkers Market through 2033?
◆ Who are the key players in the Blood Based Biomarkers Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Fabian
Email: fabian@datamintelligence.com
Phone USA: +1 877-441-4866
Phone UK: +44 161-870-5507
Website:https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.